Table IV.

Effect of prophylactic administration of anti-LBP mAbs on survival and on plasma TNF levels in d-galactosamine-sensitized mice challenged with LPSa

Deaths/TotalPlasma TNF (pg/ml)a
Saline11 /16 (69%)910 ± 360
mAbs
1A0 /16 (0%)c55 ± 60d
1B3 /16 (18%)c230 ± 280b,d
2A0 /16 (0%)c30 ± 15d
2B1 /16 (6%)c40 ± 30d
3A9 /16 (56%)600 ± 470
3B10 /16 (62%)840 ± 690
  • a Mice received an i.v. injection of 100 μg of mAbs or saline 15 min prior to LPS challenge (expt. 1, 30 ng/mouse; expt. 2, 50 ng/mouse). Data are a pool of the two experiments, with eight mice per treatment group. The χ2 test indicated a significant difference in survival between the groups (p < 0.04).

  • b TNF levels in mice treated with clone 1B were different from those of mice treated with clones 1A, 2A, and 2B.

  • c p < 0.02 by Fisher’s exact test comparing mice receiving saline with mice receiving mAbs. According to an ANOVA comparing the seven treatment groups: 1) p = 7 × 10−9, 2) p = 3 × 10−8.

  • d p < 0.05 indicates statistical difference over other groups by ANOVA.